848 results on '"Erbersdobler, Andreas"'
Search Results
2. The miR-183/96/182 cluster is upregulated in glioblastoma carrying EGFR amplification
3. Hautpathologie
4. Weibliche Gynäkopathologie
5. Urologische Pathologie
6. Mammapathologie
7. Erkrankungen der Leber und des Pankreas
8. Erkrankungen des Knochenmarks und des lymphatischen Systems
9. Wichtige histologische Färbungen
10. Erkrankungen des Magen-Darm-Traktes
11. Tumoren des ZNS und PNS
12. Erkrankungen der Lunge
13. Familiäre Tumorsyndrome
14. Endokrine Pathologie
15. Weichgewebs- und Knochentumoren
16. Tumoren des Kindes- und Jugendalters
17. Surgery for Valvular and Nonvalvular Papillary Fibroelastomas
18. Infektiöse Krankheitsursachen (belebte Noxen)
19. Hypertrophie, Hyperplasie, Atrophie
20. Immunpathologie
21. Entzündung
22. Pathologische Regeneration
23. Blutgefäße und Herzinfarkt
24. Kreislaufstörungen
25. Nekrosen
26. Allgemeine Histologie ausgewählter Organe
27. Nichtepitheliale Tumoren
28. Epitheliale Tumoren
29. Rare germline variants in the E-cadherin gene CDH1 are associated with the risk of brain tumors of neuroepithelial and epithelial origin
30. EGFR and BRAF mutations in inverted sinonasal papilloma — a more complex landscape?
31. Loss of Mismatch-repair Protein Expression and Microsatellite Instability in Upper Tract Urothelial Carcinoma and Clinicopathologic Implications
32. Kurs Spezielle Pathologie
33. Frequent and Yet Unreported GNAQ and GNA11 Mutations are Found in Uveal Melanomas
34. Pathology, Molecular Biology, and Prognosis of Penile Squamous Cell Carcinoma: What Can We Learn from the Specimen?
35. E2F1 Signalling is Predictive of Chemoresistance and Lymphogenic Metastasis in Penile Cancer: A Pilot Functional Study Reveals New Prognostic Biomarkers
36. Pathologic Features of Tumor Activity and Stability in Uveal Melanoma Specimens after Fractionated CyberKnife Radiosurgery
37. ERBB2 Amplification as a Predictive and Prognostic Biomarker in Upper Tract Urothelial Carcinoma
38. Pathologic Evaluation and Reporting of Carcinoma of the Penis
39. Kurs Allgemeine Pathologie
40. Supplementary Data Figure 12 from Determination of Microvessel Density by Quantitative Real-time PCR in Esophageal Cancer: Correlation with Histologic Methods, Angiogenic Growth Factor Expression, and Lymph Node Metastasis
41. Supplementary Data Figure 6 from Determination of Microvessel Density by Quantitative Real-time PCR in Esophageal Cancer: Correlation with Histologic Methods, Angiogenic Growth Factor Expression, and Lymph Node Metastasis
42. Supplementary Data Figure 9 from Determination of Microvessel Density by Quantitative Real-time PCR in Esophageal Cancer: Correlation with Histologic Methods, Angiogenic Growth Factor Expression, and Lymph Node Metastasis
43. Supplementary Data Figure 2 from Determination of Microvessel Density by Quantitative Real-time PCR in Esophageal Cancer: Correlation with Histologic Methods, Angiogenic Growth Factor Expression, and Lymph Node Metastasis
44. Supplementary Data Figure 7 from Determination of Microvessel Density by Quantitative Real-time PCR in Esophageal Cancer: Correlation with Histologic Methods, Angiogenic Growth Factor Expression, and Lymph Node Metastasis
45. Supplementary Data Figure 5 from Determination of Microvessel Density by Quantitative Real-time PCR in Esophageal Cancer: Correlation with Histologic Methods, Angiogenic Growth Factor Expression, and Lymph Node Metastasis
46. Supplementary Data Figure 8 from Determination of Microvessel Density by Quantitative Real-time PCR in Esophageal Cancer: Correlation with Histologic Methods, Angiogenic Growth Factor Expression, and Lymph Node Metastasis
47. Supplementary Data Figure 3 from Determination of Microvessel Density by Quantitative Real-time PCR in Esophageal Cancer: Correlation with Histologic Methods, Angiogenic Growth Factor Expression, and Lymph Node Metastasis
48. Supplementary Data Figure 4 from Determination of Microvessel Density by Quantitative Real-time PCR in Esophageal Cancer: Correlation with Histologic Methods, Angiogenic Growth Factor Expression, and Lymph Node Metastasis
49. Data from Targeting Activin Receptor-Like Kinase 1 Inhibits Angiogenesis and Tumorigenesis through a Mechanism of Action Complementary to Anti-VEGF Therapies
50. Supplementary Methods, Figures 1-6, Tables A-C from Targeting Activin Receptor-Like Kinase 1 Inhibits Angiogenesis and Tumorigenesis through a Mechanism of Action Complementary to Anti-VEGF Therapies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.